SAN DIEGO and TORONTO, March 06, 2018 -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, and Gregory K. Chow, Senior Vice President and Chief Financial Officer, will participate at the upcoming conferences:
- Cowen and Company 38th Annual Healthcare Conference
| Time: | 12:00 p.m. EDT | ||
| Date: | Monday, March 12, 2018 | ||
| Location: | The Boston Marriott Copley Place, Boston, MA | ||
| Live webcast: | http://wsw.com/webcast/cowen46/apto/ | ||
- 30th Annual ROTH Conference
| Time: | 9:30 a.m. PDT | ||
| Date: | Tuesday, March 13, 2018 | ||
| Location: | The Ritz Carlton, Laguna Niguel, CA | ||
| Live webcast: | http://wsw.com/webcast/roth32/apto/ | ||
- 2018 B. Riley & Co. China Healthcare Investment Partnering Symposium
| Time: | 11:30 a.m. CST (China Standard Time) | ||
| Date: | Friday, March 16, 2018 | ||
| Location: | The Intercontinental Hotel, Hangzhou, People’s Republic of China | ||
| Live webcast: | http://wsw.com/webcast/brileyco20/apto/ | ||
- Oppenheimer 28th Annual Healthcare Conference
| Time: | 8:00 a.m. EDT | ||
| Date: | Wednesday, March 21, 2018 | ||
| Location: | The Westin Grand Central, New York, NY | ||
| Live webcast: | https://veracast.com/webcasts/opco/healthcare2018/76201109497.cfm | ||
The audio webcasts can also be accessed through the Aptose website at www.aptose.com and will be archived shortly after the live event and available for 90 days.
About Aptose Biosciences
Aptose Biosciences is a clinical-stage biotechnology company committed to developing personalized therapies addressing unmet medical needs in oncology. Aptose is advancing new therapeutics focused on novel cellular targets on the leading edge of cancer. The company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. For further information, please visit www.aptose.com.
For further information, please contact:
Aptose Biosciences
Greg Chow, CFO
647-479-9828
Email: [email protected]
| SMP Communications Susan Pietropaolo 201-923-2049 [email protected] | LifeSci Advisors Michael Wood Managing Director 646-597-6983 [email protected] |


Infineon Raises 2026 Revenue Outlook as AI Data Center Demand Fuels Record Quarterly Sales
Meta Ordered to Pay $567M Over Child Safety Violations in New Mexico
DHL Q2 Profit Jumps 24% as Express Business Drives Growth
OpenAI Restricts Astra AI Over Cyberattack Risks
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback
Nintendo Shares Jump as Switch 2 Sales Boost Earnings
Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium
DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management
SpaceX Targets Starship Flight 14 With First V3 Starlink Satellite Launch 



